Briobacept |
| カタログ番号GC72394 |
Briobacept（BR 3 FC）は、B細胞アポトーシスを誘導するBLyS（BAFF）に対する選択的ヒトモノクローナル抗体である。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 869881-54-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Briobacept blocks circulating BLyS, thus inhibiting B cell activation and promoting B cell apoptosis[3].
Briobacept (100 μg/mouse; i.p.; for 5 d) inhibits basal NF-κB2 activation in wild-type mice[4].
Briobacept (100 μg/mouse; i.p.; 3 times per week for 5 weeks) inhibits p52 generation and development of spontaneous lupus-like disease in NZB/WF1 mice[4].
References:
[1]. Sifuentes Giraldo WA, et al. New targets in systemic lupus (part 2/2). Reumatol Clin. 2012 Sep-Oct;8(5):263-9.
[2]. Liu Yunjie, et al. Research progress on the pathogenesis and drug targeting therapy of B lymphocyte stimulator-induced rheumatoid arthritis. 2011;22(33):3152-3154.
[3]. La Cava A. Targeting B cells with biologics in systemic lupus erythematosus. Expert Opin Biol Ther. 2010 Nov;10(11):1555-61.
[4]. Kayagaki N, et al. BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. Immunity. 2002 Oct;17(4):515-24.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *